Standard Biotools Inc.
LAB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001162194
In the last 90 days, Standard Biotools Inc. insiders filed 1 open-market purchase and 0 sales; 143 institutions reported holding it in 13F filings for Q2 2026, worth $243.6M in total; Viking Global Investors is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:12 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $74.9M (87.8% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 11, 2022 |
| Revenue | $85.3M | $174.4M | $106.3M | $97.9M | $130.6M |
| Cost of revenue | $42.8M | $90.2M | $55.9M | – | – |
| Gross profit | $42.5M | $84.3M | $50.5M | – | – |
| Operating expenses | $152.8M | $259.5M | $127.0M | $214.2M | $198.0M |
| Research and development | $26.0M | $62.4M | $25.9M | $38.5M | $37.9M |
| Selling, general and administrative | $109.9M | $156.6M | $87.5M | $114.8M | $98.9M |
| Operating income | -$110.2M | -$175.2M | -$76.6M | -$116.2M | -$67.5M |
| Interest expense | – | – | $4.57M | $4.33M | $3.82M |
| Income tax | -$37.9M | $573.0K | $452.0K | -$2.83M | -$4.42M |
| Net income | -$74.9M | -$138.9M | -$74.7M | -$190.1M | -$59.2M |
| EPS, basic | $-0.20 | $-0.52 | $-0.94 | $-2.43 | $-0.78 |
| EPS, diluted | $-0.20 | $-0.52 | $-0.94 | $-2.43 | $-0.78 |
| Weighted shares, basic | 381.6M | 353.2M | 79.2M | 78.3M | 75.8M |
| Weighted shares, diluted | 381.6M | 353.2M | 79.2M | 78.3M | 75.8M |
| Margins and growth | |||||
| Gross margin | 49.9% | 48.3% | 47.4% | – | – |
| Operating margin | -129.2% | -100.5% | -72.0% | -118.6% | -51.7% |
| Net margin | -87.8% | -79.6% | -70.2% | -194.1% | -45.4% |
| Revenue growth, year over year | −51.1% | +64.0% | +8.6% | −25.0% | −5.5% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023! | FY2022! | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 11, 2022 |
| Cash and equivalents | $120.9M | $166.7M | $51.7M | $81.3M | $28.5M |
| Short-term investments | – | – | – | $84.5M | – |
| Accounts receivable | $13.4M | $33.6M | $19.7M | $17.3M | $18.3M |
| Inventory | $20.0M | $40.7M | $20.5M | $21.5M | $20.8M |
| Total current assets | $454.3M | $375.9M | $158.2M | $208.8M | $72.1M |
| Property, plant and equipment | $19.3M | $42.6M | $24.2M | $25.7M | $28.0M |
| Goodwill | – | $111.3M | $106.3M | $106.3M | $106.4M |
| Intangible assets | – | $29.0M | $1.40M | $12.6M | $27.9M |
| Total assets | $567.8M | $612.3M | $323.1M | $390.3M | $275.2M |
| Accounts payable | $5.41M | $12.3M | $9.24M | $7.91M | $10.6M |
| Total current liabilities | $108.3M | $65.9M | $109.3M | $43.4M | $49.6M |
| Long-term debt | – | $299.0K | $63.5M | – | – |
| Total liabilities | $143.5M | $140.6M | $159.9M | $160.5M | $180.6M |
| Shareholders' equity | $424.3M | $471.7M | -$148.1M | -$81.5M | $94.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 11, 2022 |
| Operating cash flow | -$74.3M | -$143.5M | -$43.3M | -$89.4M | -$44.1M |
| Capital expenditures | $8.30M | $8.36M | $2.83M | $3.83M | $13.3M |
| Free cash flow | -$82.6M | -$151.8M | -$46.1M | -$93.2M | -$57.3M |
| Depreciation and amortization | $9.26M | $12.3M | $12.7M | $6.22M | $3.65M |
| Stock-based compensation | $29.6M | $31.7M | $13.1M | $14.9M | $16.1M |
| Share buybacks | $0 | $40.5M | $5.41M | $563.0K | – |
| Investing cash flow | $27.4M | $363.2M | $20.2M | -$88.1M | -$11.9M |
| Financing cash flow | $570.0K | -$102.6M | -$6.81M | $230.8M | $16.0M |
| Net change in cash | -$45.5M | $116.3M | -$29.8M | $52.9M | -$40.1M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 34.7% | 18.2% | 12.3% | 15.2% | 12.3% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 1, 2026 | 394.8M | +2.7% | SEC |
| Aug 3, 2026 | 392.6M | +2.8% | SEC |
| Mar 12, 2026 | 390.1M | +2.9% | SEC |
| Nov 2, 2025 | 384.6M | +3.3% | SEC |
| Aug 15, 2025 | 382.0M | +2.9% | SEC |
| May 1, 2025 | 379.8M | +2.1% | SEC |
| Mar 2, 2025 | 379.0M | +30.6% | SEC |
| Nov 1, 2024 | 372.3M | +368.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.